Journal of Oncology

Cancer Metastasis: A Therapeutic Target


Publishing date
01 Jan 2019
Status
Published
Submission deadline
07 Sep 2018

1China Medical University, Taichung, Taiwan

2Tunghai University, Taichung, Taiwan

3Central University of Tamil Nadu, Tamil Nadu, India

4University of California, Oakland, USA

5University of Texas, Austin, USA


Cancer Metastasis: A Therapeutic Target

Description

This special issue aims to publish articles covering the broader research area of cancer metastasis and will be an invaluable resource for anyone working in the field of cancer and interested in cancer metastasis. Metastasis to vital organs from cancers of breast, lung, liver, colon, melanoma, and prostate is responsible for 90% of all cancer deaths. Patients diagnosed with metastatic disease have an extremely poor prognosis, with a 10-year survival rate of only 5–10%. This special issue would discuss the cancer metastasis. Clinical and translational advances pertaining to the metastatic process may be thwarted by our poor understanding of the molecular and biochemical mechanisms involved in the process of metastasis. Metastasis is a complex multistep sequential process involving invasion of cancer cells, intravasation, circulation, arrest in the capillary bed of secondary organ, and colonization at the secondary site. Experimental studies have shown that, among all the cancer cells injected into the circulation, very few have the capacity to successfully metastasize to a distant organ. This inefficiency in metastatic ability has been attributed to crucial rate-limiting steps of metastasis specifically the host immune system in the circulation, extravasation, and postextravasation survival in colonization. Cells that metastasize to secondary sites may not necessarily proliferate immediately and could remain dormant for a long period until the microenvironment at the secondary site becomes congenial for its proliferation. The mechanisms underlying the metastatic spread of cancer, including the orchestrated programs coordinating cell migration and dissemination throughout disease progression, remain unclear.

Therefore, the main aim and scope of this special issue are to discuss the various factors including adhesion proteins/EMT/target therapy that specifically affect metastasis, metastasis suppressor, or metastasis promoters; it would provide insights into the molecular mechanisms of metastasis and could launch clinical translational initiatives. A deeper understanding of the molecular concepts and processes involved in metastasis may pave the way toward new prognostic models and ways of planning treatment.

We especially welcome original research papers (in vitro, in vivo, or phase II trials) or systematic or meta-analytic reviews addressing unique technological advances to treat the cancer metastasis by using targeted therapy and well-being of cancer patients after primary treatment in the below mentioned areas. All submitted manuscripts will undergo rigorous peer review to assess their suitability for publication. This special issue is open for a very limited number of articles, which preferably describe and report significant advancement in the current state of the art in the above-mentioned areas.

Potential topics include but are not limited to the following:

  • Hallmarks of cancer metastasis
  • Epithelial-mesenchymal transition in cancer metastasis: mechanism and its clinical importance
  • Cancer metastasis treatment using target therapy
  • Suppression of signal transducer to inhibit growth of metastasis

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 7907282
  • - Editorial

Cancer Metastasis: A Therapeutic Target

Peramaiyan Rajendran | Wei-Ting Chao | ... | Kalayarasan Srinivasan
  • Special Issue
  • - Volume 2019
  • - Article ID 9367845
  • - Review Article

iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers

Houdong Zuo
  • Special Issue
  • - Volume 2019
  • - Article ID 5247837
  • - Research Article

Sequential Interventional Management of Osseous Neoplasms via Embolization, Cryoablation, and Osteoplasty

Sri Hari Sundararajan | Steven Calamita | ... | Sudipta Roychowdhury
  • Special Issue
  • - Volume 2019
  • - Article ID 6375025
  • - Research Article

Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis

Alicja Trebinska-Stryjewska | Lukasz Szafron | ... | Ewa A. Grzybowska
  • Special Issue
  • - Volume 2019
  • - Article ID 3253696
  • - Research Article

Use of Antimetastatic SOD3-Mimetic Albumin as a Primer in Triple Negative Breast Cancer

Shanta M. Messerli | Amanda M. Schaefer | ... | W. Keith Miskimins
  • Special Issue
  • - Volume 2019
  • - Article ID 6280347
  • - Review Article

Liver Metastases and Histological Growth Patterns: Biological Behavior and Potential Clinical Implications—Another Path to Individualized Medicine?

Rui Caetano Oliveira | Henrique Alexandrino | ... | José Guilherme Tralhão
  • Special Issue
  • - Volume 2019
  • - Article ID 5689464
  • - Research Article

Interaction of CD200 Overexpression on Tumor Cells with CD200R1 Overexpression on Stromal Cells: An Escape from the Host Immune Response in Rectal Cancer Patients

Atil Bisgin | Wen-Jian Meng | ... | Xiao-Feng Sun
  • Special Issue
  • - Volume 2018
  • - Article ID 1953571
  • - Research Article

The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma

Sung Han Kim | Eun Young Park | ... | Jinsoo Chung
  • Special Issue
  • - Volume 2018
  • - Article ID 6273947
  • - Review Article

Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

Xinzhe Yu | Jichun Gu | ... | Chen Jin
  • Special Issue
  • - Volume 2018
  • - Article ID 1912438
  • - Research Article

A Machine Learning Approach for the Association of ki-67 Scoring with Prognostic Factors

E. Dirican | E. Kiliç
Journal of Oncology
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision136 days
Acceptance to publication68 days
CiteScore3.900
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.